Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 4/20 | 0.42 |
| ▸ | TRPV3 | Q8NET8 | 9/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22321627 | 0.79 | KIF11 (0.47) | KIF11TRPV3 | |
| SCHEMBL22321650 | 0.75 | GSTO1 (0.40) | KIF11TRPV3LTA4HKDM1AMAOB | |
| SCHEMBL2558500 | 0.75 | MGLL (0.43) | KIF11TRPV3 | |
| SCHEMBL5650095 | 0.73 | SCN9A (0.46) | ENPP1KIF11TRPV3TOP1 | |
| SCHEMBL22337682 | 0.72 | TRPV3 (0.43) | TRPV3LTA4H | |
| SCHEMBL27616958 | 0.71 | KIF11 (0.47) | KIF11TRPV3CASP3LTA4HTOP1 | |
| SCHEMBL22321603 | 0.71 | KDM1A (0.39) | KIF11TRPV3KDM1AMAOB | |
| SCHEMBL22321579 | 0.71 | KDM1A (0.39) | KIF11TRPV3KDM1AMAOB | |
| SCHEMBL22321552 | 0.71 | KDM1A (0.39) | KIF11TRPV3KDM1AMAOB | |
| SCHEMBL12938512 | 0.70 | KIF11 (0.45) | ENPP1KIF11LMNATHRBCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | UNIV AMIENS PICARDIE JULES VERNE (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | QDPR, PNMT, CYP3A43 | ENPP1 1764/4885KIF11 3487/4885TRPV3 221/4885 |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | QDPR, PNMT, CYP3A43 | ENPP1 2450/4885KIF11 3467/4885TRPV3 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.